Improved sensitivity to activated protein C following postmenopausal hormone replacement therapy.
De Mitrio
V
V
Marino
R
R
Giannoccaro
F
F
Galantino
P
P
Cicinelli
E
E
D000279:Administration, Cutaneous; D000328:Adult; D000368:Aged; D001777:Blood Coagulation / Q000187:drug effects*; D004198:Disease Susceptibility; D004359:Drug Therapy, Combination; D004958:Estradiol / Q000008:administration & dosage / Q000494:pharmacology*; D015914:Estrogen Replacement Therapy; D005165:Factor V / Q000032:analysis; D005169:Factor VIII / Q000032:analysis; D005260:Female; D006801:Humans; D017258:Medroxyprogesterone Acetate / Q000008:administration & dosage / Q000494:pharmacology*; D008875:Middle Aged; D010314:Partial Thromboplastin Time; D017698:Postmenopause; D011486:Protein C / Q000502:physiology*; D017293:Protein S / Q000032:analysis; D019851:Thrombophilia / Q000517:prevention & control*
D011486:Protein C; D017293:Protein S; C035876:factor V clotting antigen; D004958:Estradiol; D005165:Factor V; D005169:Factor VIII; D017258:Medroxyprogesterone Acetate